
    <!DOCTYPE html>
    <html>
    <head>
        <style>
            body { 
                font-family: 'Segoe UI', Roboto, -apple-system, sans-serif; 
                max-width: 1200px; 
                margin: 0 auto; 
                padding: 20px; 
                background-color: #f0f2f5;
                line-height: 1.6;
            }
            .container { 
                background-color: white; 
                padding: 40px; 
                border-radius: 16px; 
                box-shadow: 0 4px 12px rgba(0,0,0,0.1);
            }
            .agent-section { 
                margin-bottom: 35px; 
                padding: 25px; 
                border-radius: 12px; 
                transition: all 0.3s ease;
            }
            .agent-section:hover {
                transform: translateY(-2px);
                box-shadow: 0 4px 15px rgba(0,0,0,0.1);
            }
            .final-annotation { 
                background-color: #f0f7ff; 
                border-left: 5px solid #2196f3; 
            }
            .validator { 
                background-color: #f0fdf4; 
                border-left: 5px solid #22c55e; 
            }
            .formatting { 
                background: linear-gradient(145deg, #fff7ed, #ffe4c4);
                border-left: 5px solid #f97316; 
                box-shadow: 0 4px 15px rgba(249, 115, 22, 0.1);
            }
            h2 { 
                color: #1a2b3c; 
                margin-top: 0; 
                font-size: 1.5rem;
                font-weight: 600;
                display: flex;
                align-items: center;
                gap: 10px;
            }
            ul { 
                margin: 15px 0; 
                padding-left: 20px; 
            }
            pre { 
                background-color: #f8fafc; 
                padding: 20px; 
                border-radius: 8px; 
                overflow-x: auto;
                font-family: 'Consolas', 'Monaco', monospace;
                font-size: 0.9rem;
                line-height: 1.5;
            }
            .validation-result { 
                font-weight: 600; 
                color: #16a34a; 
                padding: 12px 20px;
                background-color: #dcfce7; 
                border-radius: 8px; 
                display: inline-block;
                margin: 10px 0;
            }
            br { 
                margin-bottom: 8px; 
            }
            p {
                margin: 12px 0;
                color: #374151;
            }
            .summary-content {
                display: flex;
                flex-direction: column;
                gap: 24px;
            }
            .summary-item {
                display: flex;
                flex-direction: column;
                gap: 8px;
                background: rgba(255, 255, 255, 0.7);
                padding: 16px;
                border-radius: 12px;
                backdrop-filter: blur(8px);
                box-shadow: 0 2px 8px rgba(0, 0, 0, 0.05);
            }
            .summary-label {
                font-weight: 600;
                color: #c2410c;
                font-size: 0.95rem;
                text-transform: uppercase;
                letter-spacing: 0.5px;
            }
            .summary-value {
                color: #1f2937;
                font-size: 1.1rem;
                padding: 8px 16px;
                background-color: rgba(255, 255, 255, 0.9);
                border-radius: 8px;
                display: inline-block;
                box-shadow: 0 1px 3px rgba(0, 0, 0, 0.1);
            }
            .summary-list {
                margin: 0;
                padding-left: 24px;
                list-style-type: none;
            }
            .summary-list li {
                color: #1f2937;
                padding: 8px 0;
                position: relative;
            }
            .summary-list li:before {
                content: "‚Ä¢";
                color: #f97316;
                font-weight: bold;
                position: absolute;
                left: -20px;
            }
            .report-header {
                text-align: center;
                margin-bottom: 40px;
                padding-bottom: 30px;
                border-bottom: 2px solid rgba(249, 115, 22, 0.2);
            }
            
            .report-title {
                font-size: 2.5rem;
                font-weight: 800;
                color: #1a2b3c;
                margin: 0;
                padding: 0;
                background: linear-gradient(135deg, #f97316, #c2410c);
                -webkit-background-clip: text;
                -webkit-text-fill-color: transparent;
                letter-spacing: -0.5px;
            }
            
            .report-subtitle {
                font-size: 1.1rem;
                color: #64748b;
                margin-top: 8px;
                font-weight: 500;
            }
            .scoring { 
                background: linear-gradient(145deg, #f0fdf4, #dcfce7);
                border-left: 5px solid #22c55e;
                box-shadow: 0 4px 15px rgba(34, 197, 94, 0.1);
            }
            .scoring-content {
                display: flex;
                flex-direction: column;
                gap: 16px;
                color: #1f2937;
                line-height: 1.8;
            }
            .scoring-content br + br {
                content: "";
                display: block;
                margin: 12px 0;
            }
            .empty-list {
                color: #6b7280;
                font-style: italic;
            }
            .error-message {
                color: #dc2626;
                padding: 12px;
                background-color: #fef2f2;
                border-radius: 6px;
                border-left: 4px solid #dc2626;
            }
            .score-badge {
                background: linear-gradient(135deg, #22c55e, #16a34a);
                color: white;
                padding: 8px 16px;
                border-radius: 12px;
                font-size: 1.5rem;
                font-weight: 700;
                display: inline-block;
                margin: 12px 0;
                box-shadow: 0 4px 12px rgba(34, 197, 94, 0.2);
                position: relative;
                top: -10px;
            }
            .score-badge::before {
                content: "Score:";
                font-size: 0.9rem;
                font-weight: 500;
                margin-right: 8px;
                opacity: 0.9;
            }
        </style>
    </head>
    <body>
        <div class="container">
            <div class="report-header">
                <h1 class="report-title">CASSIA Analysis Report</h1>
                <p class="report-subtitle">Comprehensive Cell Type Analysis and Annotation</p>
            </div>
            
                <div class="agent-section final-annotation">
                    <h2>üîç Final Annotation Analysis</h2>
                    To annotate the cell type based on the provided ranked marker list from a single-cell human dataset derived from breast cancer tissue, we will follow the outlined steps:<br><br>### Step 1: List the Key Functional Markers<br>- **IGKC, IGHG1, IGHG3, IGHG4, IGHGP, IGHM, IGHA1, IGLC3, IGLC2, JCHAIN**: These are immunoglobulin genes, which are critical components of antibodies. They are involved in the immune response, specifically in the recognition and neutralization of pathogens.<br>- **MZB1**: Known as Marginal Zone B and B1 Cell-Specific Protein, it is involved in the regulation of immunoglobulin secretion.<br>- **TNFRSF17 (BCMA)**: A receptor for B-cell activating factor, important for B-cell development and survival.<br>- **FCRL5**: A member of the Fc receptor-like family, involved in the regulation of B-cell function.<br>- **CD79A, CD79B**: Components of the B-cell receptor complex, essential for B-cell activation.<br>- **POU2AF1 (BOB.1/OBF.1)**: A transcriptional coactivator involved in B-cell development.<br>- **CD38**: A multifunctional enzyme involved in cell adhesion, signal transduction, and calcium signaling, often expressed on plasma cells.<br>- **SLAMF7**: A receptor involved in the activation of immune cells, including B-cells and plasma cells.<br>- **PRDM1 (Blimp-1)**: A transcription factor critical for the differentiation of B-cells into plasma cells.<br>- **CD27**: A member of the TNF-receptor superfamily, important for the generation and long-term maintenance of T-cell immunity, but also expressed on memory B-cells.<br>- **ISG20**: An interferon-stimulated gene involved in antiviral responses.<br>- **MEF2C**: A transcription factor involved in the regulation of immune cell differentiation.<br>- **CCND2**: Cyclin D2, involved in cell cycle regulation, often upregulated in proliferating cells.<br>- **HSP90B1**: A heat shock protein involved in protein folding and stress responses.<br><br>### Step 2: List the Key Cell Type Markers<br>- **Immunoglobulin genes (IGKC, IGHG1, IGHG3, etc.)**: Strongly indicative of B-cells, particularly plasma cells, which are responsible for antibody production.<br>- **MZB1, PRDM1, CD38, SLAMF7**: Markers associated with plasma cells, the antibody-secreting cells derived from B-cells.<br>- **CD79A, CD79B**: Indicative of B-cells, as they are part of the B-cell receptor complex.<br>- **POU2AF1**: Associated with B-cell development and differentiation.<br>- **TNFRSF17, FCRL5**: Markers associated with mature B-cells and plasma cells.<br><br>### Step 3: Cross-reference Known Databases<br>Using databases such as the Human Cell Atlas, CellMarker, and literature on scRNA-seq data from breast cancer tissues, the expression of these markers is consistent with B-cells, particularly plasma cells. Plasma cells are known to express high levels of immunoglobulin genes and markers like CD38, PRDM1, and SLAMF7.<br><br>### Step 4: Determine the Most Probable General Cell Type<br>Based on the expression of immunoglobulin genes and other B-cell/plasma cell markers, the most probable general cell type is **B-cells**, with a strong indication towards **plasma cells**.<br><br>### Step 5: Identify the Top 3 Most Probable Sub Cell Types<br>1. **Plasma Cells**: Given the high expression of immunoglobulin genes, CD38, PRDM1, and SLAMF7, plasma cells are the most likely subtype.<br>2. **Memory B-cells**: The presence of CD27 and other B-cell markers suggests the possibility of memory B-cells, although the high immunoglobulin expression leans more towards plasma cells.<br>3. **Mature B-cells**: While less likely due to the high expression of plasma cell-specific markers, mature B-cells could be a possibility given the presence of CD79A/B and POU2AF1.<br><br>### Step 6: Provide a Concise Summary of Your Analysis<br>The ranked marker list from the breast cancer tissue dataset strongly indicates the presence of B-cells, with a predominant expression pattern characteristic of plasma cells. The high levels of immunoglobulin genes, along with markers such as CD38, PRDM1, and SLAMF7, support this annotation. While memory B-cells and mature B-cells are considered, the evidence overwhelmingly points to plasma cells as the most likely subtype.<br><br>**FINAL ANNOTATION COMPLETED**
                </div>
            
                <div class="agent-section validator">
                    <h2>‚úì Validation Check</h2>
                    <div class="validation-result">‚úÖ VALIDATION PASSED</div>
                    Validation result: VALIDATION PASSED<br><br>The proposed annotation result is consistent with the provided marker list and the identified cell type. Here's the breakdown:<br><br>1. **Marker Consistency**: <br>   - The key functional markers listed in the annotation result, such as IGKC, IGHG1, IGHG3, MZB1, TNFRSF17, FCRL5, CD79A, CD79B, POU2AF1, CD38, SLAMF7, PRDM1, CD27, ISG20, MEF2C, CCND2, and HSP90B1, are all present in the provided marker list.<br>   - These markers are consistent with B-cells, particularly plasma cells, as they are involved in immunoglobulin production, B-cell activation, and plasma cell differentiation.<br><br>2. **Mixed Cell Type Consideration**:<br>   - The annotation result considers the possibility of mixed cell types, such as memory B-cells and mature B-cells, but the evidence strongly supports plasma cells as the predominant subtype. The high expression of immunoglobulin genes and plasma cell-specific markers like CD38, PRDM1, and SLAMF7 justifies this conclusion.<br>   - There is no strong evidence of multiple distinct cell types that would necessitate flagging for further investigation.<br><br>Overall, the annotation is well-supported by the marker list and aligns with known characteristics of B-cells and plasma cells.
                </div>
            
                        <div class="agent-section formatting">
                            <h2>üìã Summary</h2>
                            
                        <div class="summary-content">
                            <div class="summary-item">
                                <span class="summary-label">Main Cell Type:</span>
                                <span class="summary-value">B-cells</span>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Sub Cell Types:</span>
                                <ul class="summary-list">
                                    <li>Plasma Cells</li><li>Memory B-cells</li><li>Mature B-cells</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Possible Mixed Cell Types:</span>
                                <ul class="summary-list">
                                    <li class="empty-list">No mixed cell types identified</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Number of Markers:</span>
                                <span class="summary-value">50</span>
                            </div>
                        </div>
                    
                        </div>
                    
                    <div class="agent-section scoring">
                        <h2>üéØ Quality Assessment</h2>
                        <div class="score-badge">90</div>
                        <div class="scoring-content">
                            The annotation results provided are scientifically accurate and well-reasoned, demonstrating a strong understanding of the markers and their implications for cell type identification. The analysis correctly identifies the presence of B-cells, with a strong emphasis on plasma cells, which is consistent with the high expression of immunoglobulin genes and other plasma cell-specific markers such as CD38, PRDM1, and SLAMF7. This is a key strength, as these markers are critical for identifying plasma cells, which are antibody-secreting cells derived from B-cells.<br><br>The annotation also considers the possibility of mixed cell types, such as memory B-cells and mature B-cells, which is a balanced approach given the presence of markers like CD27 and CD79A/B. However, the analysis rightly concludes that plasma cells are the predominant subtype, given the overwhelming evidence from the marker list.<br><br>One potential area for improvement is the consideration of the rank of the markers. While the analysis does a good job of identifying key markers, it could place more emphasis on the markers that appear first in the list, as these are likely to be more important. For example, IGKC and IGHG1 are among the first markers listed and are crucial for identifying plasma cells, which should be highlighted more prominently in the analysis.<br><br>Overall, the annotation provides a comprehensive view of the cell types present, with no obvious misclassifications or oversights. The use of multiple markers is well-balanced, and the analysis captures the general picture of the cell populations effectively.<br>
                        </div>
                    </div>
                
        </div>
    </body>
    </html>
    